Have a feature idea you'd love to see implemented?
Let us know!
TNFA TNF Pharmaceuticals Inc.
Price (delayed)
$1.36
Market cap
$3.75M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$13.72
Enterprise value
$2.57M
mymd is a clinical stage biotech pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms. mymd-1 is a drug platform based on a clinical stage
Highlights
The company's debt has shrunk by 80% YoY and by 29% QoQ
TNF Pharmaceuticals's equity has increased by 8% YoY
The quick ratio fell by 33% QoQ but it rose by 2% YoY
The EPS has plunged by 158% YoY and by 27% from the previous quarter
The company's net income fell by 34% QoQ
Key stats
What are the main financial stats of TNFA
Market
Valuations
Earnings
Shares outstanding
2.76M
Market cap
$3.75M
Enterprise value
$2.57M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.19
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$23.66M
EBITDA
-$23.66M
Free cash flow
-$10.14M
Per share
Balance sheet
Liquidity
EPS
-$13.72
Free cash flow per share
-$4.2
Book value per share
$7.08
Revenue per share
$0
TBVPS
$5.61
Total assets
$24.04M
Total liabilities
$6.99M
Debt
$18,285
Equity
$16.78M
Working capital
$5.04M
Debt to equity
0
Current ratio
1.72
Quick ratio
1.52
Net debt/EBITDA
0.05
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-139.7%
Return on equity
-295.2%
Return on invested capital
-650.5%
Return on capital employed
-138.7%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TNFA stock price
How has the TNF Pharmaceuticals stock price performed over time
Intraday
10.57%
1 week
10.62%
1 month
-17.07%
1 year
-84.04%
YTD
-82.47%
QTD
-16.05%
Financial performance
How have TNF Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$12.89M
Net income
-$23.66M
Gross margin
N/A
Net margin
N/A
The company's net income fell by 34% QoQ
TNFA's operating income is up by 16% year-on-year and by 14% since the previous quarter
Growth
What is TNF Pharmaceuticals's growth rate over time
Valuation
What is TNF Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.19
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has plunged by 158% YoY and by 27% from the previous quarter
The stock's P/B is 98% below its last 4 quarters average of 11.3 and 97% below its 5-year quarterly average of 5.9
TNF Pharmaceuticals's equity has increased by 8% YoY
Efficiency
How efficient is TNF Pharmaceuticals business performance
TNFA's ROIC is down by 34% since the previous quarter
The ROA has contracted by 21% from the previous quarter
TNF Pharmaceuticals's return on equity has decreased by 20% QoQ
Dividends
What is TNFA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TNFA.
Financial health
How did TNF Pharmaceuticals financials performed over time
The total liabilities has shrunk by 73% QoQ but it has increased by 22% YoY
The quick ratio fell by 33% QoQ but it rose by 2% YoY
The company's debt is 100% lower than its equity
The debt to equity has dropped by 100% since the previous quarter and by 100% year-on-year
The company's debt has shrunk by 80% YoY and by 29% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.